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Abstract. Disease modifying drugs for Alzheimer’s disease (AD) are likely to be most effective when given in non-demented
subjects. In this review we summarized biomarkers in cerebrospinal fluid (CSF) and blood that can predict AD-type dementia
in subjects with mild cognitive impairment (MCI). In addition, we investigated whether these markers could reduce sample size
and costs if used to select subjects for trials on the prevention of AD in subjects with MCI. A meta-analysis of markers that had
been investigated in multiple studies showed that the combination of amyloid-β (Aβ)1−42 and tau in CSF had the best predictive
accuracy for AD (odds ratio (OR) 18.1, 95% confidence interval (CI) 9.6–32.4). Aβ1−42, total tau, and phosphorylated tau in CSF
also predicted conversion, but with lower accuracy (OR 7.5 to 8.1). Plasma levels of Aβ1−40, Aβ 1−42, the ratio Aβ1−42/Aβ1−40
and homocysteine did not predict outcome. In a fictive trial design, the use of the combination of Aβ1−42 and tau in CSF in the
selection of subjects could reduce sample size by 67% and trial costs by 60% compared to a trial in which unselected subjects
with MCI would be enrolled. In conclusion, the combination of Aβ1−42 and tau in CSF is useful to select subjects for trials that
aim to slow down the progression from MCI to AD-type dementia.
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INTRODUCTION
Disease modifying drugs that may slow down the
progression of Alzheimer’s disease (AD) are currently
under development. These drugs are likely to be most
effective when given early in the course of the disease,
but diagnostic criteria for AD in non-demented sub-
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jects are presently lacking. Predementia AD cannot
be accurately diagnosed by clinical criteria alone, such
as criteria for mild cognitive impairment (MCI) [1,2].
Biomarkers may help to increase the diagnostic accu-
racy compared to clinical criteria [3], because patho-
logical changes of AD can already be found in non-
demented subjects [4]. However, which biomarkers
would be most useful as inclusion criterion in trials
with disease modifying drugs and to what extent these
markers could reduce sample size and costs of such
trials is unknown.
The aim of the present study was to investigate which
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biomarkers could predict AD-type dementia in subjects
with MCI and how the use of these biomarkers as an
inclusion criterion for trials with drugs that aim to slow
down the progression from MCI to AD-type dementia,
could reduce sample size and costs. We limited our
study to biomarkers in cerebrospinal fluid (CSF) and
blood.
First, we will briefly summarize the pathophysiology
in AD, since appropriate biomarkers should reflect AD
pathology [5]. Next, we will discuss biomarkers for the
key pathological processes in AD in CSF and blood and
discuss their use as predictor for progression to AD-
type dementia in subjects with MCI. Of CSF and blood
markers that have been investigated in at least four
studies, we will calculate pooled measures of predictive
accuracy. Finally, we will use the predictive accuracy
of the best markers to calculate for a fictive trial how
the use of these markers as an inclusion criterion will
influence sample size and costs.
PATHOPHYSIOLOGY OF AD
Abnormalities in amyloid-β (Aβ) processing play
a central role in the pathophysiology of AD. In AD,
Aβ peptides aggregate and form oligomers, fibrils, and
eventually plaques, a pathological hallmark of AD. Ag-
gregated Aβ is supposed to be neurotoxic and to initiate
a cascade of events including oxidative stress, inflam-
mation, and dysregulation of lipid metabolism. This
cascade eventually leads to loss of synapses and cell
death, as shown in Fig. 1 [6]. Different isoforms of the
Aβ peptide are generated from the amyloid-β protein
precursor (AβPP). In AD, Aβ1−42 seems to be partic-
ularly important as it is more prone to aggregate com-
pared to other isoforms. Cumulating evidence suggests
that the oligomer form of Aβ is toxic [7]. The increase
in aggregated Aβ may be caused by either increased
production, disturbance of the post-translational mod-
ification, or reduced clearance of Aβ. Neurofibril-
lary tangles are another pathological hallmark of AD.
These are aggregates of hyperphosphorylated tau and
may contribute to neuronal dysfunction. Inflammato-
ry processes, oxidative stress, and alteration of lipid
metabolism are thought to occur as a consequence of
Aβ pathology, but may in turn further dysregulate Aβ
processing. The primary cause for dysregulation of Aβ
metabolism is unknown and multiple factors may be
involved, for example genetic or environmental factors.







Altered amyloid-β  metabolism
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Fig. 1. Pathophysiology of Alzheimer’s disease.
BIOMARKERS FOR AD IN SUBJECTS WITH
MCI
Many of the biochemical changes related to the
pathophysiology of AD can be measured in vivo in body
fluids.
Markers for Aβ processing in CSF
Biomarkers for Aβ processing in CSF include iso-
forms of the peptide itself as well as markers for its
production and clearance. Aβ peptides can be mea-
sured with assays that measure monomers or aggregat-
ed species, or with assays that are not specific for ag-
gregation status [8–10]. The concentration of Aβ 1−42
correlates with the presence of amyloid plaques in the
brain [11]. Many studies have shown that in MCI sub-
jects, a low concentration of Aβ1−42 in CSF can pre-
dict conversion to AD-type dementia, as will be dis-
cussed in more detail below. Also a combination of
different Aβ isoforms in CSF may predict AD-type
dementia in subjects with MCI [12]. Production of
Aβ1−42 from AβPP is dependent on the β-site AβPP
cleaving enzyme (BACE-1). One study showed that
increased BACE1 activity could predict AD-type de-
mentia in MCI subjects [13]. Of the peptides that may
be involved in the clearance of Aβ only few have been
investigated in CSF of subjects with MCI. Levels of
neprilysin were decreased in subjects with progressive
MCI and mild AD-type dementia compared to con-
trols [14]. Aβ binding proteins may also influence
Aβ aggregation and a lower level of serum amyloid P
component predicted AD-type dementia in MCI sub-
jects [15].
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Markers for Aβ processing in plasma
In plasma, abnormal Aβ concentrations have been
associated with AD, although they do not correlate with
the occurrence of Aβ plaques in the brain [16,17]. Four
longitudinal studies have assessed predictive value of
plasma Aβ levels in MCI subjects, as will be discussed
in more detail below. In a small study, the AβPP iso-
form ratio in platelets could predict conversion to AD-
type dementia in MCI subjects with a sensitivity and
specificity of 0.83 [18].
Markers for neurodegeneration
Many markers of neurodegeneration are available,
but most of them are not specific for AD pathology.
Concentrations of total tau (t-tau) and phosphorylat-
ed tau (p-tau) can be measured in CSF and correlate
with the presence of neurofibrillary tangles [11,19]. In
MCI subjects, increased CSF level of t-tau and p-tau
were associated with an increased risk of progression
to AD-type dementia as will be discussed below. In
plasma, levels of tau are very low and no reliable assay
is available yet. Other markers for neurodegeneration,
like visinin-like protein, neurofilaments, and GAP43
(neuromodulin), are increased in CSF of AD subjects
compared to controls [20], but have not been tested as
predictor for AD-type dementia in subjects with MCI.
Markers for inflammation
A wide range of inflammatory markers have been
studied in blood and CSF of AD subjects, including
cytokines, acute-phase proteins, and complement fac-
tors, but none of these markers could discriminate be-
tween subjects with AD and healthy controls [21–24].
In MCI, CSF tumor necrosis factor α (TNF-α) was in-
creased and transforming growth factor β (TGFβ) was
decreased in subjects progressing to AD-type demen-
tia compared to healthy controls, but not compared to
subjects with stable MCI [25]. Another study showed
higher levels of TNF receptors in CSF as well as in
plasma in MCI subjects that converted to AD-type de-
mentia [26,27]. Several other cytokines did not predict
progression to AD-type dementia [25,28].
Antibodies against Aβ are found in CSF and plasma
of AD subjects. Studies comparing levels of antibodies
of AD subjects and healthy controls showed conflicting
results [21]. The possible use of antibodies as marker
in MCI has not been studied yet.
Markers for oxidative stress
Some markers of lipid peroxidation, protein oxida-
tion, and nitrosylation and DNA and RNA oxidation
have shown to be abnormal in CSF, plasma, or pe-
ripheral blood cells of subjects with AD-type demen-
tia [29]. In MCI subjects, an increased level of F2-
isoprostane, a marker of lipid peroxidation, was associ-
ated with cognitive decline and progression to AD-type
dementia [30].
Markers for lipid metabolism
Serum cholesterol is suggested to be associated with
an increased risk for AD, but results have been con-
flicting [31]. In CSF, increased levels of 24OHC and
27-hydroxycholestrol (27OHC) were found in AD and
MCI subjects compared to controls [32–35]. In plas-
ma, results have been conflicting [31]. One study in
MCI found that CSF levels of sulfatide and the ratio
of sulfatide to phosphatidylinositol were decreased in
very mildly demented subjects [36]. However, the pre-
dictive accuracy for AD-type dementia in subjects with
MCI has not yet been tested.
Other markers
Homocysteine
Increased plasma homocysteine may be associated
with an increased risk for AD, although the exact patho-
physiological mechanism behind this is not clear [37].
Two studies found an association between homocys-
teine level and incidence of AD in the general popula-
tion [38,39]; another study found no association of plas-
ma homocysteine level and the incidence of MCI [40].
The predictive accuracy of homocysteine for AD-type
dementia in subjects with MCI will be discussed in
more detail below.
Proteomics
Unbiased approaches have been useful to select
biomarkers in CSF or plasma that may differentiate be-
tween AD subjects and healthy controls [23]. In CSF, a
panel of 17 proteins and peptides in CSF could distin-
guish between subjects with stable MCI and subjects
with MCI who progressed to AD-type dementia [41].
In plasma, a combination of 18 different proteins in
plasma predicted progression to AD-type dementia in
MCI subjects with over 90% accuracy [42]. However,
in a subsequent study that tested for reproducibility of
these markers, diagnostic accuracy was lower [43].
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Table 1
Baseline characteristics of studies included in the meta-analysis of CSF biomarkers in subjects with MCI
Study N Age MMSE Follow up Markers from each study




Riemenschneider (2002) [59] 28 70.1 (8.1) 27.4 (1.5) 1.5 4 −
Hampel (2003) [50] 52 72.5 (8.3) 28.9 (1) 0.7 (0.4) 1,2 1,2
Tarowski (2003) [25] 56 74.0 (7.5) 28.6 (1.5) 0.8 (range 0.2–3.0) − 1,2
Zetterberg (2003) [61] 53 range 50–83 27.0 (1.7) 1.7 (0.8) 2,4 −
Maruyama (2004) [55] 57 73.9 (6.2) 25.7 (1.3) 2.0 (0.4) 2 2
Herukka (2005) [53] 78 70.4 (7.4) − 3.0 (range 0.5–12) 1–4 1,2,3
Hansson (2006) [52] 134 71.8 (range 50–86) 27.0 (1.6) 4.7 (range 1.1–6.8) 3,4 1,2,3
Parnetti (2006) [58] 55 − − 1.0 1–3 1,2,3
Ewers (2007) [47] 88 70.9 (7.3) 27.0 (2.0) 1.8 (0.8) 3 −
Fellgiebel (2007) [48] 16 68.6 (7.9) 25.7 (2.7) 1.6 (0.8) 3 2,3
Hansson (2007) [52] 134 71.8 (range 50–86) 27.1 (1.6) 4.7 (range 1.1–6.8) 1 −
Schonknecht (2007) [60] 80 69.3 (7.8) 26.6 (1.6)  1 − 2,3
Forsberg (2008) [49] 21 63.3 (7.8) 28.2 (1.4) 0.7 (0.5) 1–3 1,2,3
Blom (2009) [45] 58 62.9 (8.2) − 4.5 (2.4) 4 1,2,3
Brys (2009) [46] 65 71.8 (7.9) 27.8 (1.8) 2.0 (0.6) 2–4 2,3
Kester (2009) [54] 100 67.8 (8.2) 26.6 (2.4) 1.5 1,2 −
Mattsson (2009) [56] 750 69.0 (range 43–89) 27.0 (range 16–30) 3.0 (range 2–11) 1–4 −
Papaliagkas (2009) [57] 53 67.7 (7.8) 27.8 (range 24–29) 0.9 (0.5) 1 −
Visser (2009) [4] 108 70 (7.7) 26.5 (2.6) 2.1 (0.7) 4 −
Data are mean (SD), unless otherwise specified.
MMSE = Mini-Mental State Examination.
*1 = Aβ1−42, 2 = Total tau, 3 = Phosphorylated tau, 4 = Combination of Aβ1−42 with total tau or phosphorylated tau.
Table 2
Effect sizes of biomarkers in CSF or plasma for prediction of Alzheimer’s disease in subjects with
MCI
Number of Number of subjects Cohen’s delta p-value
studies (AD at follow-up/ (95% CI)
no-AD at follow-up)
CSF
Aβ1−42 7 172/252 0.84 (0.45–1.24) < 0.001
t-tau 11 238/404 0.90 (0.62–1.17) < 0.001
p-tau 8 161/316 1.21 (0.85–1.57) < 0.001
Plasma
Aβ1−40 4 133/215 0.18 (−0.06–0.41) 0.15
Aβ1−42 4 133/215 0.05 (−0.24–0.35) 0.72
Ratio Aβ1−42/Aβ1−40 4 133/215 −0.08 (−0.32–0.16) 0.25
Homocysteine 4 79/229 0.19 (−0.13–0.50) 0.52
AD = Alzheimer type dementia; CSF = cerebrospinal fluid; Aβ1−42 = amyloid-β peptide 1–42;
Aβ1−40 = amyloid-β peptide 1–40; t-tau = total tau; p-tau = phosphorylated tau.
POOLED ANALYSIS OF PREDICTORS FOR
AD IN SUBJECTS WITH MCI
We performed a meta-analysis of markers that had
been tested in at least four studies to obtain pooled
estimates of the predictive accuracy for progression to
AD-type dementia in subjects with MCI. These markers
were Aβ1−42, t-tau, and p-tau in CSF and Aβ1−40,
Aβ1−42, and homocysteine in plasma.
We identified studies through a systematic search in
PubMed, Medline, and Psychinfo (search terms avail-
able on request) and from the references of retrieved
studies. If multiple studies reported on the same sam-
ple, we included the study with the longest follow up or
the largest sample size. Data were pooled in a random
effects model with STATA (version 9.2; Stata Corp,
College Station, TX). For continuous variables, we cal-
culated Cohen’s delta as outcome measure [44]. For di-
chotomized scores, we calculated the sensitivity, speci-
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Table 3
Characteristics of studies included in the meta-analysis of plasma markers in subjects with
MCI
Study N Age MMSE Follow up (year)
Aβ1−42 and Aβ1−40
Hansson (2008) [63] 117 69.7, range 50–85 27.0 (1.6) 5.2
Hansson (2008) [63] 110 62.9, range 47–79 27.0 (1.6) Range 2–4
Lopez (2008) [64] 42 79.8 (4.3) − 4.5
Cammarata (2009) [62] 79 75.2 (5.2) > 26 2.0
Homocysteine
Maruyama (2004) [55] 57 73.9 (5.7) 25.6 (1.3) 2.0
Annerbo (2006) [65] 91 65.0 (8.5) 26.4 (2.6) 6.0
Gabryelewicz (2007) [66] 105 69.3 (6.9) 27.3 (1.8) 3.0
Siuda (2009) [67] 55 70.8 (5.7) − 1.0
Data are mean (SD), unless otherwise specified.
MMSE = Mini Mental State Examination; Aβ1−42 = amyloid-β peptide 1-42; Aβ1−40 =
amyloid-β peptide 1-40.
ficity, positive predictive value, and odds ratio (OR).
These dichotomized scores were based on cut-offs pro-
vided in the study. If different types of cut-off lev-
els were used within one study, we chose predefined
cut-offs over data-driven cut-offs.
Aβ1−42, t-tau, and p-tau in CSF
We identified 19 studies [4,25,45–61] which provid-
ed unique data on CSF levels of Aβ1−42, t-tau, and
p-tau as predictors for AD-type dementia in subjects
with MCI (Table 1). One multi-center study may have
included data that had been presented in other studies
as well [56], but exclusion of this study did not change
the outcome substantially and therefore the study was
included in the analyses.
The mean conversion rate to AD-type dementia in the
studies was 37% during a mean follow up of 2.5 years.
Cohen’s delta showed that Aβ1−42, t-tau, and p-tau
were significant predictors of outcome (Table 2). The
highest OR for AD-type dementia was found for the
combination of Aβ1−42 and t-tau with or without p-tau
(OR 18.1, 95% confidence interval (CI) 9.6–34.2). An
abnormal combination was defined as an abnormal ratio
of these markers or as an abnormal score for at least two
markers. The combination Aβ1−42 with only p-tau had
a slightly lower OR (17.5, 95% CI 10–30.6). For the
individual markers, the OR ranged from 7.54 (Aβ 1−42)
to 8.05 (p-tau). For further analysis we selected the
combination of Aβ1−42 and t-tau, which was studied in
eight studies with a total of 1,236 MCI subjects of which
454 converted to AD-type dementia. The sensitivity
of this combination to predict AD-type dementia was
0.87 (95% CI 0.80–0.95), the specificity 0.70 (95% CI
0.57–0.83), and the positive predictive value 0.65 (95%
CI 0.53–0.77).
Aβ1−40 and Aβ1−42 in plasma
We selected four studies on the association of Aβ
plasma levels with conversion to AD-type dementia in
subjects with MCI [62–64] in which a total of 348 sub-
jects with MCI was included (Table 3). The mean con-
version rate to AD-type dementia was 38% during a
mean follow up of 3.6 years. The pooled effect sizes
for Aβ1−40, Aβ1−42, and the ratio Aβ1−42/Aβ1−40
and conversion to AD-type dementia are shown in Ta-
ble 2. None of the effect sizes was statistically signif-
icant, although increased levels of Aβ1−40 showed a
weak association with conversion to AD-type dementia
(Cohen’s delta 0.18, p = 0.15, Table 3, Fig. 2). No
dichotomized scores were available.
Homocysteine in plasma
Four studies [55,65–67] with a total of 308 sub-
jects investigated the predictive value of homocysteine
for AD-type dementia in subjects with MCI (Table 3).
Mean conversion rate to AD-type dementia was 25%
during a mean follow up of 3.3 years. Homocysteine
did not predict AD-type dementia (Cohen’s delta 0.19,
Table 2). No dichotomized scores were available.
USE OF BIOMARKERS IN SELECTION
SUBJECTS FOR DRUG TRIALS
In the previous section, we showed that the combina-
tion of Aβ1−42 and tau in CSF had the best predictive
accuracy to predict conversion to AD-type dementia in
subjects with MCI. In this section we will investigate
how the use of these markers for the selection of sub-
jects can reduce sample size and costs of a trial with a
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Fig. 2. Pooled Cohen’s delta of Aβ40 plasma levels for the prediction
of AD-type dementia in subjects with MCI. A positive Cohen’s delta
indicates that increased plasma levels are associated with an increased
risk for AD.
drug that could slow down the progression from MCI
to AD-type dementia. We compare the costs of two
strategies. The first strategy is a trial in which subjects
with MCI are included. The second strategy is a trial in
which subjects are enrolled with MCI and an abnormal
combination of Aβ1−42 and tau in CSF. Calculations
will be performed from the perspective of the performer
of the trial and input estimates are mainly based on
expert opinion.
The hypothetical trial is a 3-year placebo-controlled
trial with 50% on active treatment to examine the ef-
fectiveness of an oral drug on the delay of progression
to AD-type dementia in subjects with MCI. Subjects
would be selected from a memory clinic setting, with
MCI defined as an abnormal performance on neuropsy-
chological tests in the absence of dementia [68]. Costs
needed to apply the trial inclusion and exclusion cri-
teria (including cognitive tests and imaging) are esti-
mated on 700 per patient. Costs for the collection
and analysis of CSF are estimated at 324. The costs
of the treatment phase of the trial were estimated to
be 5800 per included patient. This included costs
for seven assessments with clinical and cognitive test-
ing and blood analysis and costs related to drugs, drug
supply, approval of the medical ethical committee, and
subject reimbursement. Costs related to side effects
and adverse events were not included in the analysis.
The number of subjects was chosen such that the
study could detect a relative decrease of 20% in con-
version rate to AD-type dementia over the 3-year peri-
od, with a power of 90%, a 2-sided alpha of 5%, and
a drop-out rate of 30%. The number of subjects to be
included would depend on the conversion rate to AD-
type dementia in each strategy. Based on the meta-
analysis above, we estimated that the 3-year conversion
rate would be 40% in subjects with MCI and 70% in
subjects with MCI and an abnormal Aβ and tau in CSF.
Based on these conversion rates, the number of subjects
to be included in the trial would be 2160 for a study
with only subjects with MCI (strategy 1) and 714 for a
study with subjects with MCI and an abnormal combi-
nation of Aβ1−42 and tau in CSF (strategy 2). Based on
a sensitivity of 0.87 and a specificity of 0.70 of the CSF
test (see previous section) and a failure rate of lumbar
puncture of 10%, 1503 subjects with MCI should un-
dergo lumbar puncture in order to include 714 subjects
with an abnormal combination of Aβ1−42 and tau in
CSF. The strategies are visualized in Fig. 3. This figure
shows the rounded number of subjects for each arm,
while costs were calculated based on the unrounded
number of subjects.
The trial costs of strategy 1 with only subjects with
MCI included would be 14,040,000 (pre-trial screen-
ing costs and trial costs for 2160 subjects, Fig. 3). The
trial costs of strategy 2 in which subjects with MCI and
an abnormal combination of Aβ1−42 and tau in CSF
are included would be 5,681,580 (pre-trial screening
costs and CSF collection and analysis costs for 1503
subjects, and trial costs for 714 subjects, Fig. 3). This
is a reduction in costs of 60% compared to strategy 1.
A one-way sensitivity analysis using the lower bound
of the confidence interval of the test-sensitivity (0.80
instead of 0.87) mentioned above would increase the
number of subjects by 208 and trial costs by 536,194
(reduction costs compared to strategy 1 of 56% instead
of 60%). Using the lower bound of the specificity (0.57
instead of 0.70) would increase the number of subjects
by 261 and trial costs by 1,704,852 (reduction costs
compared to strategy 1 of 47%). If the lower bound
of positive predictive value was used (0.58 instead of
0.70), 839 extra subjects needed to be included and trial
costs would increase by 3,171,554 (reduction costs
compared to strategy 1 of 37%). A CSF test-price in-
crease of 25% resulted in an increase of 121,743 of the
total trial costs (reduction costs compared to strategy 1
of 59%). If trial costs would double to 11,600 per pa-
tient, strategy 2 would reduce costs by 63% compared
to strategy 1.
DISCUSSION
Our main findings are that the combination of
Aβ1−42 with total tau in CSF is the best predictor for
conversion from MCI to AD-type dementia and that
use of these markers in the selection of subjects for tri-
als with drugs that aim to prevent the progression from




Fig. 3. Costs related to different recruitment strategies in a hypothetical trial. Strategy 1 refers to a trial in which subjects with MCI are included
and strategy 2 to a trial in which subjects with MCI and an abnormal Aβ1−42/tau ratio in CSF are included. It is assumed that 40% of the subjects
with MCI would convert to AD at follow-up. The number of subjects with a positive and negative test result are based on a sensitivity of 0.87
and a specificity of 0.70 as explained in the text. The rounded number of subjects in each arm is shown, while costs were calculated based on the
unrounded numbers of subjects. Test positive = number of subjects with abnormal CSF ratio; test negative = number of subjects with normal
CSF ratio; test failed = number of subjects in which lumber puncture failed (10% of sample).#Subjects included in trial.
MCI to AD trials can substantially reduce the sample
size and trial costs.
Although a large variety of biomarkers for AD can
quantify dysregulation of Aβ metabolism or secondary
processes in AD like neurodegeneration, inflammation,
oxidative stress, and altered lipid metabolism in CSF
and blood, only few of them have been tested as pre-
dictor for AD-type dementia in subjects with MCI in
more than four independent studies. Among the mark-
ers tested in multiple studies, the combination Aβ1−42
with t-tau in CSF had the best predictive accuracy. CSF
levels of Aβ1−42, t-tau, and p-tau could also predict
conversion to AD-type dementia but the accuracy was
lower. Plasma levels of Aβ1−40, Aβ1−42, the ratio
of Aβ1−42/Aβ1−40, and homocysteine levels did not
predict AD-type dementia.
In our hypothetical trial on the prevention of progres-
sion from MCI to AD-type dementia, use of Aβ1−42
and tau in CSF for the selection of subjects could re-
duce trial costs up to 60% relative to a trial that would
include subjects with MCI that were not selected by
CSF markers. This reduction largely resulted from the
fact that fewer subjects were needed to be enrolled in
order to obtain the required statistical power. The sam-
ple size could be smaller because the conversion rate in
subjects with MCI and abnormal Aβ1−42 and tau levels
(70%) was much higher compared to that in unselected
subjects with MCI (40%). The sensitivity analysis con-
firmed the strong effect of conversion rate on costs, as
the cost reduction of a model with a conversion rate of
58% in subjects with abnormal Aβ1−42 and tau levels
would be much lower (37%). The sensitivity analyses
also showed that the costs of the CSF test had only a
minor influence on the cost reduction and that bene-
fits would be larger if the costs for conducting the trial
increased.
Our study has several limitations. We may have
overestimated the predictive accuracy of the CSF mark-
ers as some studies included in the meta-analysis di-
chotomized scores according to the best cut off in their
study. There were differences in study design between
the pooled studies but it was outside the scope of the
present paper to explore the effect of this variability on
the predictive accuracy. Our meta-analysis was based
on relatively few studies, which reduced the accuracy
of the parameter estimates. Therefore, we used low-
er bound estimates in the sensitivity analyses of the
cost calculations. Still, these were one-way sensitivity
analyses and not full sensitivity analyses. Our cost-
calculation did not take into account costs associated
with side effects of lumbar puncture. The most com-
mon side effect is post-lumbar headache in less than
3% of the subjects, which occasionally needs interven-
tion [69].
We calculated the effect on costs when CSF markers
were used to select subjects for treatment trials. How-
ever, when CSF markers are used to select subjects
for treatment outside the clinical trial setting, the cost-
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benefit could be markedly different. In that case, costs
need to be calculated from a societal perspective, which
includes all costs and effects related to the disease, such
as medication use, caregiver time, patient and caregiver
quality of life and institutionalization. The cost reduc-
tion of the use of CSF tests in the selection of subjects
for treatment in such a setting is likely to be much low-
er as subjects with a false-negative diagnosis or sub-
jects that could not undergo the diagnostic test would
not receive treatment and could not benefit from the
reduction in societal costs associated with treatment.
Clinical implications
Our findings suggest that the design of trials on the
prevention of progression from MCI to AD-type de-
mentia could have a higher cost-benefit ratio if sub-
jects are included based on abnormal CSF markers. A
possible disadvantage of the use of CSF markers, how-
ever, is that the logistics of such trial could become
more complex. CSF collection may not be available in
all settings and subjects may refuse to undergo lumbar
puncture or have a contraindication for it. In addition,
facilities should be set-up for central analysis of CSF
samples, which can provide a standardized cut-off [70].
If lumbar puncture is performed on a large scale, rare
side effects may become apparent.
Future perspectives
Since lumbar puncture is relatively invasive, a plas-
ma biomarker for AD would be more attractive. So
far attempts to develop an accurate plasma AD marker
have been unsuccessful. It seems unlikely that new
biomarkers in either CSF or blood may reach or im-
prove the diagnostic accuracy of that of Aβ1−42 and
tau in CSF in the near future. New markers that have
been tested in subjects with AD-type dementia versus
healthy control have generally yielded a lower diagnos-
tic accuracy compared to Aβ1−42 and tau in CSF. A
promising alternative may be the combination of dif-
ferent plasma or CSF markers or gene expression pro-
files, but so far replication of such multiparameter ap-
proaches has been difficult [43]. Development of di-
agnostic markers from proof of concept to large-scale
application may take up to 15 years, as was the case
for Aβ1−42 and tau in CSF. Future studies should com-
pare the use of CSF makers in trials with that of other
diagnostic modalities such as PET or MRI imaging.
Finally, it should be investigated whether biomarkers
could increase the cost-benefit ratio in the selection of
subjects in prevention trials in subjects without MCI or
outside a clinical setting, in which the conversion rate
to AD-type dementia is much lower.
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